Abstract
• ▶ antipsychotic drugs • ▶ sexual dysfunction • ▶ sexual side eff ects • ▶ treatment-emergent sexual dysfunction Sexual Dysfunction Related to Psychotropic Drugs: A Critical Review Part II: Antipsychotics antipsychotic medication: until a few years ago, this problem was largely neglected by research teams [ 1 -4 ] , and sexual side eff ects induced by antipsychotic medication received only modest attention [ 5 , 6 ] . The reasons for this are several. Firstly, previous research tended to focus mainly on the eff ects of the underlying disease on the patient's sexuality, describing sexual disorders and behaviour associated with psychotic symptoms [ 7 -9 ] . Secondly, patients, especially those suff ering from schizophrenia, rarely spontaneously report sexual dysfunction [ 10 ] . In addition, similar to patients taking antidepressants, patients with psychosis are more likely to report sexual side eff ects if directly questioned about them. Studies that relied only on spontaneous reporting of side eff ects, report low rates of sexual dysfunction, while studies using structured interviews or questionnaires show higher rates of sexual dysfunction [ 3 , 11 , 12 ] . Despite this fi nding, in clinical practice psychiatrists often continue to underestimate the importance of formally enquiring about sexual dysfunction among their patients. It should be noted that some researchers [ 13 -18 ] included iatrogenic endocrine disorders (amenorrhea, galactorrhea and gyne-
Introduction and Methods

▼
This study was conducted using the paper and electronic resources of the library of the Azienda Provinciale per i Servizi Sanitari (APSS) in Trento, Italy ( http://atoz.ebsco.com/Titles/2793 ). The library has access to a wide range of databases including (DYNAMED, MEDLINE Full Text, CINAHL Plus Full Text), The Cochrane Library, Micromedex healthcare series, BMJ Clinical Evidence. The full list of available journals can be viewed at http://atoz.ebsco.com/Titles/2793 , or at the APSS web site ( http://www.apss.tn.it ). In completing this review, a literature search was conducted using the key words "antipsychotic drugs", "psychotropic drugs", "sexual dysfunctions", "sexual side eff ects", "treatment-emergent sexual dysfunction". All resulting listed articles were reviewed. comastia) in their defi nition of sexual dysfunction which is not in keeping with international classifi cations (ICD-10, DSM-IV-TR), and which may therefore have aff ected the data on prevalence rates.
Also, the defi nition of sexual dysfunction ( • ▶ Table 1 ) used by some investigators [ 13 , 14 , 16 , 18 ] included only "decreased libido" and "impotence/sexual dysfunction", without considering other areas of sexual dysfunction. Despite this, psychiatrists frequently do not address issues relating to the sexual health of their patients [ 9 , 19 -23 ] and they are uncomfortable [ 24 ] or reluctant to discuss this subject [ 3 , 22 ] with the result that the prevalence of sexual dysfunction is underestimated [ 14 , 23 , 25 -28 ] . Sexual side eff ects however, increase the risk of inadequate compliance or discontinuation of drug therapy: in fact, they are one of the most important factors associated with poor compliance with treatment [ 29 -37 ] . The burden of sexual dysfunction is not only relevant to drug compliance: sexual functioning impacts signifi cantly on quality of life. Sexual dysfunction secondary to the use of antipsychotics can adversely aff ect quality of life and therefore is an important outcome measure of treatment. The data on antipsychotic-induced sexual dysfunction tend to show high and variable prevalence rates. Baggaley [ 30 ] identifi ed that between 30 % and 80 % of female schizophrenic patients and between 45 % and 80 % of male schizophrenic patients reported impaired sexual functioning. Other studies have documented much higher rates: for example those of Macdonald et al. [ 38 ] (82 % of men and 96 % of women) and Fan et al. [ 39 ] (between 65 % and 94 % for both sexes, depending on the diff erent scales used). Other studies have reported lower rates: approximately 58 % of men and 33 % of women in the study by Ghadirian et al. [ 40 ] , 59 .3 % of men and 49.1 % of women in the study by Fujii et al. [ 41 ] while only 10 % (for both sexes) in the research by Knegtering et al. [ 42 ] . The variation in prevalence rates is related to several factors, but is mainly due to the diff erent methodological approaches adopted by diff erent studies: studies that relied only on spontaneous reporting of side eff ects, report low rates of sexual dysfunction, while studies using structured interviews or questionnaires show higher rates of sexual dysfunction [ 3 , 11 , 12 ] . It should be noted that some researchers [ 13 -18 ] included iatrogenic endocrine disorders (amenorrhea, galactorea and gynecomastia) in their defi nition of sexual dysfunction which is not in keeping with international classifi cations (ICD-10, DSM-IV-TR), and which may therefore have aff ected the data on prevalence rates. Also, the defi nition of sexual dysfunction used by some investigators [ 13 , 14 , 16 , 18 ] only included "decreased libido" and "impotence/sexual dysfunction", without considering other areas of sexual dysfunction.
Mechanism of action of antipsychotics on sexual function
Antipsychotic drugs exert numerous diff erent actions on cell receptors in the central nervous system (CNS). They can also cause endocrine disturbances by increasing prolactin. Diff erent hypotheses have been suggested for the mechanism of action of antipsychotics on sexual function ( • ▶ Table 2 ), including [ 3 , 20 , 23 , 30 , 43 -47 ] : (i) dopaminergic antagonist action, (ii) increased prolactin (secondary to dopaminergic antagonist action), (iii) blockage of alpha-adrenergic receptor (antiadrenergic action), (iv) blockage of acetylcholine receptors (anticholinergic action), (v) serotonin antagonist action, (vi) histamine antagonist action. Binding to dopaminergic, cholinergic, histaminergic and α-adrenergic receptors may directly aff ect sexual function by inhibiting motivation and reward, increasing sedation and reducing peripheral vasodilation [ 3 , 25 , 30 , 44 , 45 ] . Sthal [ 48 ] suggests that the neurotransmitters involved in the 3 stages (desire, arousal and orgasm) of the human sexual response cycle have diff erent mechanisms of action. For example, in stage 1 (desire), dopamine (DA) exerts a positive infl uence, while serotonin (5HT) has negative eff ects. In stage 2, several neurotransmitters facilitate sexual arousal, including norepinephrine (NE), acetylcholine (Ach), and dopamine (DA). As with desire, serotonin has a negative eff ect. Stage 3 (orgasm), is inhibited by serotonin and facilitated by norepinephrine; dopamine may have weak positive infl uences. However, the exact nature of involvement of the various neurotransmitters in antipsychotic induced sexual dysfunction remains unclear. Diff erences in receptor-affi nity profi les of antipsychotics may help explain the diff erences in their sexual side-eff ect profi les [ 49 ] . For example, antipsychotics with α-adrenergic antagonis- tic properties are associated with priapism [ 50 ] . Although antipsychotics can induce relatively isolated eff ects on the neurotransmitters involved in the response cycle, the mechanism of action leading to sexual dysfunction is more complex. Sexual side eff ects often occur in combination, and pharmacological eff ects on one component may have an indirect eff ect on another area of sexual functioning. Furthermore, the etiology of sexual dysfunction may in many cases be multifactorial [ 2 ] . Hyperprolactinemia is caused by blockage of dopamine D2 receptors in the hypothalamic infundibular system [ 51 -55 ] . Dopamine (DA) has an antagonistic eff ect on the production of prolactin (one of the hormones most implicated in sexual response). Hence, the use of antipsychotics can lead to a decrease in dopamine and a consequent rise in prolactin, which can inhibit sexual function. Sexual dysfunction is most prevalent in patients with hyperprolactinemia; a correlation between antipsychotic-induced hyperprolactinemia and sexual dysfunction rates has also been documented [ 2 , 3 , 5 , 20 , 26 , 30 , 44 , 51 , 56 -61 ] . This correlation, however, is neither confi rmed [ 15 , 62 -67 ] nor clear [ 68 , 69 ] in other studies. There have also been reported cases of sexual dysfunction with normal prolactin levels [ 70 , 71 ] : in these cases, the sexual dysfunction was probably associated with other physical (e. g., diabetes) or psychological (e. g., quality of partner relationship) factors. It is unclear whether sexual dysfunction correlates to a direct eff ect and/or an indirect eff ect of hyperprolactinemia. Increased prolactin levels, inhibit the hypothalamic release of GnRH (gonadotropin releasing hormone), a hormone that releases gonadotropins, follicle stimulating hormone (FSH) and luteinizing hormone (FSH) from the anterior pituitary gland. The end result of an increase in prolactin, may therefore consist of a reduction in levels of gonadal hormones (e. g., decreased levels of estrogen in women and testosterone in men) [ 9 , 44 , 72 ] . During long-term treatment with typical antipsychotics, it is reported that women have signifi cantly more elevated prolactin levels than men [ 73 ] . Increased prolactin levels are also more common among women [ 3 , 74 ] . Smith et al. [ 75 ] , for example, found that after 2 years on antipsychotics medication, 75 % of women and 34 % of men had high levels of prolactin. An increase in prolactin is very common among psychotic patients treated with a fi rst generation antipsychotic, but also with risperidone and amisulpride [ 3 , 23 , 59 , 76 , 77 ] . Based on these observations, some authors make the distinction between antipsychotics that elevate prolactin levels (so-called "prolactin-raising") and those that have minimal and/or transient eff ects on prolactin levels ("prolactin-sparing") ( • ▶ Table 3 ) [ 59 , 72 , 78 , 79 ] . It is worth highlighting that hyperprolactinemia is not always accompanied by clinical symptoms (such as amenorrhea, or gynecomastia) [ 73 ] . In addition to direct pharmacological eff ects (such as, for example, the antagonistic action on dopamine receptors) and endocrine dysfunction, other pharmacological side eff ects including sedation (mainly related to antihistaminergic action), extrapyramidal eff ects and weight gain, can indirectly reduce sexual desire [ 85 ] . It is diffi cult to evaluate the eff ects of antipsychotic drugs on sexual function in patients with schizophrenia because they are often superimposed on sexual impairment caused by the disease itself [ 25 ] . In a comparison group study comparing schizophrenic patients on antipsychotic medication with schizophrenic patients taking no medication and healthy individuals with no schizophrenia, there was a high rate of sexual dysfunction in both patient groups [ 86 ] .
Antipsychotics and sexual dysfunction
Antipsychotic-induced side eff ects on sexual function are usually inhibitory in nature and may aff ect all phases of the sexual response cycle. These eff ects include decreased sexual desire ("libido"), difficulties with erection, achieving orgasm and sexual satisfaction, as well as ejaculation disorders (delayed or inhibited ejaculation, retrograde ejaculation, spontaneous ejaculation in the absence of sexual stimulation, decreased ejaculatory volume) [ 20 , 72 , 85 , 87 , 88 ] . Data from the early literature generally showed that (i) all antipsychotics are associated with decreased sexual desire [ 89 ] .
(ii) Most antipsychotics are associated with erectile dysfunction. Those most frequently cited in the literature include: chlorpromazine, pimozide, thioridazine, thiotixene and sulpiride [ 90 ] . (iii) Thioridazine was probably one of the fi rst antipsychotic drugs identifi ed as having the ability to cause delayed ejaculation [ 90 ] . (iv) There are many case reports on antipsychoticinduced anorgasmia: among these, the most frequently cited antipsychotic is thioridazine [ 89 ] , followed by trifl uoperazine [ 91 ] . (v) Priapism is a possible side eff ect of all antipsychotic drugs [ 92 ] , particularly for phenothiazines (chlorpromazine, fl uphenazine and thioridazine), although more recently isolated cases have been reported with aripiprazole [ 93 ] , clozapine, fl upenthixol [ 89 ] , olanzapine, quetiapine [ 94 , 95 ] , risperidone [ 25 ] and ziprasidone [ 95 -97 ] .
To date, most of the studies conducted have been observational comparison studies of various typical and atypical antipsychotic drugs. The number of randomized controlled trials that specifi cally focus on antipsychotic induced sexual dysfunction is small [ 4 ] . The interpretation of data relating to the assessment of sexual functioning is complex because of the diff erent assessment tools and study methods adopted in the various studies, making it diffi cult to compare fi ndings. The conclusions reached by the various researchers as summarized below, are not defi nitive and they are diffi cult to interpret and need to be confi rmed by further studies [ 98 -100 ] . prolactin levels for asenapine [ 80 , 81 ] , iloperidone [ 82 ] , and lurasidone [ 83 ] In this review we have provided a summary of the main conclusions reached by studies in the current literature, as well as summarizing the most salient information on individual drugs. Serretti et al. [ 11 ] , in a recent meta-analysis (which included data on studies investigating sexual dysfunction related to treatment with antipsychotics) showed that quetiapine, ziprasidone, perphenazine and aripiprazole were associated with relatively low rates of sexual dysfunction (16-27 %), whereas olanzapine, risperidone, haloperidol, clozapine and thioridazine were associated with higher rates of sexual dysfunction (40-60 %).
In the randomized double-blind study by Kelly et al. [ 101 ] (with a sample size of only 27 patients) the side eff ects of fl uphenazine, quetiapine and risperidone were compared. Patients experienced high rates of sexual dysfunction with each of these drugs (78 % with fl uphenazine, 50 % with quetiapine, and 42 % with risperidone). Symptom improvement, mainly with regards to arousal/erection, was observed during the trial only in those patients treated with quetiapine. The authors concluded that quetiapine has a better side eff ect profi le than the other two drugs.
In a randomized open label comparison study by Knegtering et al. [ 102 ] (comparing the atypical antipsychotics, risperidone and olanzapine), 46 patients initially taking a typical antipsychotic, were switched to risperidone or olanzapine. Olanzepine was found to cause less sexual dysfunction. In a study on 199 patients using combined data from an open and combined study, Knegtering et al. [ 3 ] concluded that typical antipsychotics and risperidone (considered to be prolactinraising) are associated with higher rates of sexual dysfunction (decreased libido, problems with orgasm) compared to prolactin-sparing antipsychotics (clozapine, olanzapine, quetiapine and sertindole). In an observational study by Bobes et al. [ 103 ] conducted in Spain on 636 patients, lower rates of sexual dysfunction were found with quetiapine (18 %) compared to olanzapine (35 %), haloperidol (38 %) and risperidone (43 %). In another observational study by Uçok et al. [ 104 ] conducted on 827 stable patients, it was reported that over 50 % of patients experienced sexual dysfunction. Patients receiving poly-pharmacy experienced more severe side eff ects than those taking a single second-generation antipsychotic. In the study by Nakonezny et al. [ 105 ] (conducted on a sample of 22 men) a switch from risperidone to quetiapine was not associated with any improvement in sexual function, assessed using a 5 item questionnaire. Byerly et al. [ 106 ] using adjusted average ASEX (Arizona Sexual Experience Scale) rating scale scores, reported less severe sexual dysfunction with quetiapine compared to olanzapine and risperidone: however, these diff erences, were not clinically significant. Nagaraj et al. [ 107 ] also found no statistically signifi cant diff erences in sexual dysfunction induced by risperidone, olanzapine and quetiapine: in this study, sexual function was measured using the SFQ (Sexual Functioning Questionnaire), which revealed a reduction in overall sexual functioning in 96 % of cases for risperidone, 90 % for olanzapine and 88 % for quetiapine. Another study by Byerly et al. [ 108 ] did not show any statistically signifi cant diff erence in sexual functioning (as assessed by ASEX) after switching from risperidone to quetiapine. Dossenbach et al. [ 31 ] conducted an observational study on 3 838 patients. Sexual problems were common among all patients taking antipsychotic drugs, although there were no statistically signifi cant diff erences in prevalence: haloperidol (71 %), risperidone (68 %), quetiapine (60 %), olanzapine (56 %). In an observational study by Strouse et al. [ 109 ] , conducted over only 12 weeks, comparing risperidone, olanzapine and clozapine, a worsening of sexual performance was reported in men only for each of these 3 drugs. A study by Bitter et al. [ 110 ] showed a mild improvement in sexual function with olanzapine (compared to risperidone), which however was limited to libido. In a study by Mahmoud et al. [ 111 ] , it was reported that sexual functioning (as measured by the SR-DISF: Derogatis Interview for Sexual Function) of 42 schizophrenics improved after a switch from typical to atypical antipsychotics (amisulpride, olanzapine, quetiapine and risperidone) in spite of the fact that two of the atypical antipsychotic drugs prescribed (amisulpride and risperidone) are noted for their capacity to induce sexual dysfunction. Montejo et al. [ 112 ] conducted an observational cross-sectional study on a sample of 243 patients with a diagnosis of psychotic disorder and found (using the PRSexDQ-SalSex) that 46 % of patients experienced sexual dysfunction, among whom those treated with risperidone and typical antipsychotics had a signifi cantly increased risk of sexual dysfunction. In the • ▶ Table 4 we have summarized the eff ect of individual antipsychotic drugs on sexual dysfunction (SD).
Treatment of sexual dysfunction induced by antipsychotics
Some recommended treatment approaches for the management of sexual dysfunction induced by antipsychotic drugs include the following: (i) A thorough clinical evaluation, to exclude comorbid conditions (physical and psychiatric) or sexual dysfunction secondary to alcohol or illicit drug use or other prescribed medication. The assessment should include measurement of serum prolactin in patients presenting with side eff ects suggestive of hyperprolactinemia [ 2 , 74 ] .
(ii) Modifi cation of risk factors (where possible, avoid use of other drugs associated with sexual dysfunction, smoking cessation, abstinence from alcohol and illicit drugs, maintaining normal blood sugar levels in diabetic patients, treatment of hypertension and hypercholesterolemia). (iii) In the early phase of treatment, if possible, consider waiting for a spontaneous improvement in side eff ects [ 63 ] . (iv) Reduction in dose of antipsychotic drug responsible for side eff ects. (v) Switch to another antipsychotic drug with a more tolerable side eff ect profi le (ideally to a "prolactin-sparing" antipsychotic) [ 59 ] . (vi) Addition of symptom targeted therapy -using dopaminergic drugs (amantadine, bromocriptine, cabergoline) or drugs with specifi c eff ects on sexual functioning (such as phosphodiesterase inhibitors or yohimbine) [ 1 , 2 , 5 , 23 , 72 , 140 , 141 ] . In a study by Inder et al., selegiline was not found to alleviate symptoms of antipsychotic-induced sexual dysfunction [ 142 ] . Sildenafi l may be a useful option in the treatment of antipsychotic-induced sexual dysfunction in men [ 141 ] . In general, the evidence supporting the addition of symptomatic therapies is weak [ 1 , 2 , 143 ] .
Conclusions
▼
All antipsychotics drugs can cause sexual dysfunction, although it is extremely diffi cult to accurately determine the true prevalence. This review confi rms that antipsychotic-induced sexual This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited. dysfunction is common among patients taking antipsychotic medication. The conclusions reached by the diff erent researchers are not defi nitive and are diffi cult to interpret mainly because of the signifi cant diff erences in methods used for assessing sexual function: further studies are needed on the underlying causes and types of sexual dysfunction, and on the factors linking antipsychotic use and sexual dysfunction, in particular with regard to the specifi c mechanisms of action including alterations in prolactin levels and binding to dopaminergic, histaminergic, cholinergic, serotoninergic and α-adrenergic receptors. Some evidence suggests that second-generation antipsychotics (with some exceptions, for example, risperidone) seem to have a better sexual side eff ect profi le compared to traditional fi rst generation antipsychotics. The impact of antipsychotic-induced sexual dysfunction negatively aff ects quality of life; it has potential implications for patient adherence to medication and the success of antipsychotic treatment. Antipsychotic-induced sexual dysfunction adversely aff ects compliance, and is one of the factors that must be taken into account when selecting treatment. Further well designed randomized control trials, investigating the eff ectiveness of diff erent strategies of managing antipsychotic-induced sexual dysfunction are needed [ 144 -146 ] .
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The authors declare no confl icts of interest. Contrasting evidence exists. High SD rates ( > 50 %) similar to haloperidol or other typical antipsychotics reported in some studies [ 126 ] , but other studies report signifi cantly lower rates [ 102 ] . Some studies suggest that olanzapine may be associated with a lower incidence of SD than risperidone, amisulpride, clozapine and quetiapine. [ 3 , 13 , 16 , 106 , 110 , 127 ] . Switching from typical antipsychotics or risperidone to olanzapine may improve sexual functioning in men and women [ 128 ] . Olanzapine causes a transient increase in prolactin, which returns to normal after a few weeks in most but not all patients [ 22 , 25 ] . quetiapine Prevalence of sexual dysfunction induced by quetiapine varies between 50 % and 60 %, and is therefore similar or lower to that of risperidone [ 101 , 129 ] and similar to that of olanzapine [ 31 ] . Severity of sexual dysfunction seems to be lower compared to patients taking risperidone, haloperidol or olanzapine [ 101 , 106 , 108 , 130 , 131 , 133 ] . A case of increased libido is reported [ 132 ] . Quetiapine is not associated with increased prolactin [ 25 ] . risperidone and paliperidone.
Risperidone: high rates (60-70 %) of SD similar to those for haloperidol, other typical antipsychotics and clozapine [ 14 , 58 , 64 , 134 ] . Signifi cantly higher levels of SD compared to quetiapine and olanzapine [ 14 ] . Commonly reported SD included decreased libido, erectile dysfunction, ejaculatory problems, impaired orgasm, menstrual irregularities and decreased vaginal lubrication [ 3 , 14 , 22 , 101 , 103 , 135 ] . Risperidone tends to elevate prolactin levels: some authors have proposed that it is a dose-dependent eff ect [ 3 , 64 , 79 , 136 ] , although this is disputed by Konarzewska et al. [ 65 ] . These authors also reported markedly higher prolactin levels in patients treated with risperidone compared to those treated with olanzapine. In contrast, in the study by Eberhard et al. [ 15 ] , the authors argue that high levels of prolactin induced by risperidone, tend to decline over a period of years and that prolactin levels did not correlate signifi cantly with sexual dysfunction. Paliperidone: causes elevated prolactin levels similar to risperidone [ 137 ] . ziprasidone
No signifi cant diff erences in rates of sexual side eff ects between ziprasidone and olanzapine [ 126 ] . Switching from typical and atypical antipsychotics to ziprasidone was related to a signifi cant reduction of SD [ 138 , 139 ] .
